Evidence map›Paper›PMID 31434775›Full record

ArticleBMJ open2019

German translation, cultural adaption and validation of the unidimensional self-efficacy scale for multiple sclerosis: a study protocol.

Barbara Seebacher, Roger J Mills, Markus Reindl, Laura Zamarian, Raija Kuisma, Simone Kircher, Christian Brenneis, Rainer Ehling, Florian Deisenhammer

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Barbara SeebacherClinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria barbara.seebacher@i-med.ac.at.
Roger J MillsDepartment of Neurology, Walton Centre NHS Foundation Trust, Liverpool, UK.
Markus ReindlClinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Laura ZamarianClinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Raija KuismaSchool of Health Sciences, University of Brighton, Eastbourne, UK.
Simone KircherClinical Department of Neurology, University Hospital of Innsbruck, Innsbruck, Austria.
Christian BrenneisDepartment of Neurology, Clinic for Rehabilitation Münster, Münster, Austria.
Rainer EhlingDepartment of Neurology, Clinic for Rehabilitation Münster, Münster, Austria.
Florian DeisenhammerClinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Universität Innsbruck · ATKarl Landsteiner Society · ATInnsbruck Medical University · ATUniversity Hospital Innsbruck · ATUniversity of Brighton · GBWalton Centre · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSelf-efficacy refers to individuals' confidence in their ability to perform relevant tasks to accomplish desired goals. This is independent of their actual abilities. In people with multiple sclerosis (MS), self-efficacy has been shown to powerfully influence motivation and health-related behaviour, such as adherence to prescribed treatment or physical activity. So far, a rigorously tested German language self-efficacy questionnaire for people with MS is missing.

methodsThe purpose of this study is to translate the original Unidimensional Self-Efficacy Scale for Multiple Sclerosis (USE-MS) into German and to validate the German USE-MS (USE-MS-G). Based on Bandura's concept of self-efficacy and international guidelines for questionnaire development, the patient-led development of the pre-final German version will involve a forward-backward translation process, synthesis of translations, expert committee review and consensus with the original test developers. At two centres in Tyrol, Austria, content and face validity and cultural adaption for Austria will be established using face-to-face semistructured cognitive interviews of 30 people with MS (PwMS). A further 292 PwMS with minimal to severe disability will be tested at two timepoints to validate the USE-MS-G.

resultsMixed methods analyses will be applied. Interviews will be transcribed and analysed employing qualitative content analysis. External validity will be explored using Spearman's Rank correlation coefficients of the USE-MS-G with the 13-item Resilience Scale, General Self-Efficacy Scale, Multiple Sclerosis International Quality of Life questionnaire, Hospital Anxiety and Depression Scale and MS-specific Neurological Fatigue Index. Test-retest reliability, internal consistency and floor and ceiling effects will be evaluated. Internal validity will be examined using Rasch analysis. ETHICS AND DISSEMINATION: Ethical approval was received from the Ethics Committee of the Medical University of Innsbruck, Austria (reference number EK1260/2018; 13.12.2018). Results from this study will be disseminated to the participants and MS Societies, and to clinicians and researchers through peer-reviewed publications and conferences. STUDY REGISTRATION: ISRCTN Registry; trial ID ISRCTN14843579; prospectively registered on 02. 01. 2019; http://www.isrctn.com/ISRCTN14843579.

Indexed as

Disability EvaluationSelf EfficacyAustriaHumansInterviews as TopicMultiple SclerosisResearch DesignTranslationsValidation Studies as TopicAustriacross-cultural comparisonMultiple sclerosispatient-reported outcome measuresself efficacyvalidation studies as topic

Identifiers

PMID31434775
PMCPMC6707685
OpenAlexW2969734506

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.